DK1326633T3 - Sammensætning omfattende immunogene mikropartikler - Google Patents
Sammensætning omfattende immunogene mikropartiklerInfo
- Publication number
- DK1326633T3 DK1326633T3 DK01966829.2T DK01966829T DK1326633T3 DK 1326633 T3 DK1326633 T3 DK 1326633T3 DK 01966829 T DK01966829 T DK 01966829T DK 1326633 T3 DK1326633 T3 DK 1326633T3
- Authority
- DK
- Denmark
- Prior art keywords
- microparticles
- composition
- immunogenic microparticles
- provides
- immunogenic
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR0117A AUPR011700A0 (en) | 2000-09-14 | 2000-09-14 | Composition comprising immunogenic virus sized particles (VSP) |
AUPR4888A AUPR488801A0 (en) | 2001-05-10 | 2001-05-10 | Composition comprising immunogenic virus sized particles (vsp) |
AUPR4962A AUPR496201A0 (en) | 2001-05-14 | 2001-05-14 | Composition comprising immunogenic virus sized particles (VSP) |
PCT/AU2001/001160 WO2002022164A1 (en) | 2000-09-14 | 2001-09-14 | Composition comprising immunogenic microparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1326633T3 true DK1326633T3 (da) | 2011-07-04 |
Family
ID=27158243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01966829.2T DK1326633T3 (da) | 2000-09-14 | 2001-09-14 | Sammensætning omfattende immunogene mikropartikler |
Country Status (15)
Country | Link |
---|---|
US (3) | US20040014708A1 (da) |
EP (1) | EP1326633B1 (da) |
JP (1) | JP5198712B2 (da) |
KR (1) | KR20030055262A (da) |
CN (1) | CN100446811C (da) |
AT (1) | ATE501726T1 (da) |
AU (1) | AUPR011700A0 (da) |
CA (1) | CA2422575C (da) |
DE (1) | DE60144240D1 (da) |
DK (1) | DK1326633T3 (da) |
ES (1) | ES2363735T3 (da) |
IL (1) | IL154913A0 (da) |
NZ (2) | NZ535851A (da) |
PT (1) | PT1326633E (da) |
WO (1) | WO2002022164A1 (da) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
FR2844514B1 (fr) * | 2002-09-16 | 2007-10-19 | Neovacs | Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation |
JP2006524991A (ja) * | 2003-05-08 | 2006-11-09 | エクサイト セラピーズ インコーポレーティッド | 抗原特異的t細胞の作製および単離の方法 |
JPWO2005053740A1 (ja) * | 2003-12-02 | 2007-06-28 | 株式会社 バイオマトリックス研究所 | 免疫増強剤およびこれを用いた強化抗原 |
WO2006012695A1 (en) * | 2004-08-04 | 2006-02-09 | Panvax Limited | An immunogenic composition |
WO2007024026A1 (ja) * | 2005-08-25 | 2007-03-01 | Taiho Pharmaceutical Co., Ltd. | T細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子 |
WO2008150276A2 (en) * | 2006-09-26 | 2008-12-11 | The Board Of Regents Of The University Of Texas System | Virus coated nanoparticles and uses thereof |
RU2016137258A (ru) | 2009-04-01 | 2018-12-13 | Юниверсити Оф Майами | Композиции вакцин и способы их применения |
CN110542754A (zh) * | 2009-05-19 | 2019-12-06 | 迈阿密大学 | 用于体外抗原呈递、评估疫苗功效及生物制剂和药物的免疫毒性的组合物、试剂盒和方法 |
EA201290072A1 (ru) * | 2009-07-29 | 2012-12-28 | Бернд Хельмут Адам Рем | Полимерные частицы и их применение |
US9724405B2 (en) * | 2010-11-05 | 2017-08-08 | Novavax, Inc. | Rabies glycoprotein virus-like particles (VLPS) |
US20120189700A1 (en) * | 2011-01-19 | 2012-07-26 | Zoraida Aguilar | Nanoparticle Based Immunological Stimulation |
CN107115314B (zh) * | 2011-06-02 | 2022-04-29 | 加利福尼亚大学董事会 | 膜包封的纳米颗粒及使用方法 |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
WO2015021390A2 (en) | 2013-08-08 | 2015-02-12 | The Regents Of The University Of California | Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis |
WO2015143295A2 (en) | 2014-03-20 | 2015-09-24 | The Regents Of The University Of California | Hydrogel compositions containing toxin-absorbing or binding nanoparticles and uses thereof |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
CN107530376A (zh) | 2015-02-18 | 2018-01-02 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
WO2016176041A1 (en) | 2015-04-29 | 2016-11-03 | The Regents Of The University Of California | Detoxification using nanoparticles |
CN109069539A (zh) | 2016-02-18 | 2018-12-21 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
CN109200271B (zh) * | 2018-11-14 | 2021-01-29 | 江南大学 | 一种蛋白质及其在调控巨噬细胞免疫功能方面的应用 |
WO2020257317A1 (en) * | 2019-06-18 | 2020-12-24 | Citranvi Biosciences, Llc | Rationally engineered carrier proteins for vaccines |
WO2020257315A1 (en) * | 2019-06-18 | 2020-12-24 | Citranvi Biosciences, Llc | Multiple antigen protein displayed adjuvant systems |
CN110339350A (zh) * | 2019-07-25 | 2019-10-18 | 广州中科蓝华生物科技有限公司 | 一种抗肿瘤的联合用药物组合物及其应用 |
CA3190428A1 (en) * | 2020-07-31 | 2022-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Vaccine compositions and methods of use thereof |
WO2024097307A1 (en) * | 2022-11-01 | 2024-05-10 | Lupagen, Inc. | Devices and methods for extracorporeal cell treatment |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK143689C (da) * | 1975-03-20 | 1982-03-15 | J Kreuter | Fremgangsmaade til fremstilling af en adsorberet vaccine |
US4035316A (en) * | 1975-11-24 | 1977-07-12 | California Institute Of Technology | Cell specific, variable density, polymer microspheres |
US4170685A (en) * | 1976-03-29 | 1979-10-09 | California Institute Of Technology | Polyvinyl pyridine microspheres |
US4157323A (en) * | 1976-06-09 | 1979-06-05 | California Institute Of Technology | Metal containing polymeric functional microspheres |
US4247434A (en) * | 1978-12-29 | 1981-01-27 | Lovelace Alan M Administrator | Process for preparation of large-particle-size monodisperse |
US4438239A (en) * | 1981-03-30 | 1984-03-20 | California Institute Of Technology | Microsphere coated substrate containing reactive aldehyde groups |
SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
US4828984A (en) * | 1986-04-11 | 1989-05-09 | Flow Cytometry Standards Corporation | Composition, synthesis and use of simulated cells |
US6338853B1 (en) | 1987-04-23 | 2002-01-15 | Jean-Claude Bystryn | Anti-cancer vaccine |
US5002883A (en) * | 1987-10-30 | 1991-03-26 | Abbott Laboratories | Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents |
GB2237510B (en) | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
US5443832A (en) * | 1990-04-16 | 1995-08-22 | Institut Swisse De Recherches Experimentales Sur Le Cancer | Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response |
US5219577A (en) * | 1990-06-22 | 1993-06-15 | The Regents Of The University Of California | Biologically active composition having a nanocrystalline core |
US5178882A (en) * | 1990-06-22 | 1993-01-12 | The Regents Of The University Of California | Viral decoy vaccine |
US5334394A (en) * | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
US5665582A (en) * | 1990-10-29 | 1997-09-09 | Dekalb Genetics Corp. | Isolation of biological materials |
US5688761A (en) * | 1991-04-19 | 1997-11-18 | Lds Technologies, Inc. | Convertible microemulsion formulations |
US6129916A (en) * | 1991-04-19 | 2000-10-10 | Tanox, Inc. | Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates |
FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
ATE180407T1 (de) * | 1993-01-11 | 1999-06-15 | Dana Farber Cancer Inst Inc | Induktion der antworten zytotoxischer t- lymphozyten |
US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
EP1181937A3 (en) * | 1994-08-09 | 2004-02-04 | Cytrx Corporation | Novel vaccine adjuvant and vaccine |
AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
DE69526260T2 (de) | 1994-11-15 | 2002-10-17 | Powderject Vaccines, Inc. | Methode zur induktion der humoralen und zellulären immunantwort durch intrazelluläre zufuhr von peptidbeschichteten mikropartikeln |
CA2207961A1 (en) | 1995-01-05 | 1996-07-11 | Robert J. Levy | Surface-modified nanoparticles and method of making and using same |
WO1997003702A1 (en) * | 1995-07-21 | 1997-02-06 | Brown University Research Foundation | A method for gene therapy using nucleic acid loaded polymeric microparticles |
JP2000514086A (ja) * | 1996-07-10 | 2000-10-24 | ダンバイオシスト、ユーケー、リミテッド | 内皮への標的のための遺伝子治療送達系 |
US5789261A (en) * | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
JP5037747B2 (ja) | 1997-01-30 | 2012-10-03 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用 |
AU760034B2 (en) | 1997-08-29 | 2003-05-08 | Corixa Corporation | Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof |
US6001333A (en) | 1997-09-12 | 1999-12-14 | See; Jackie R. | Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging |
CA2318493A1 (en) | 1998-01-16 | 1999-07-22 | The Johns Hopkins University | Oral delivery of nucleic acid vaccines by particulate complexes |
SE9800615D0 (sv) | 1998-02-27 | 1998-02-27 | Ingvar Sjoeholm | Mucosal microparticle conjugate vaccine |
GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
EP1107782B1 (en) | 1998-09-01 | 2009-12-23 | Merrion Research III Limited | Oral vaccine compositions |
MXPA01007895A (es) * | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
EP1159967B1 (en) | 1999-02-09 | 2008-09-10 | Riken | Tumor vaccines |
US6551597B1 (en) * | 1999-03-18 | 2003-04-22 | President & Fellows Of Harvard College | Vaccine compositions for human papillomavirus |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
WO2000074658A1 (en) | 1999-06-02 | 2000-12-14 | Medinova Medical Consulting Gmbh | Use of drug-loaded nanoparticles for the treatment of cancers |
EP1118331A1 (en) | 2000-01-21 | 2001-07-25 | I.D.M. Immuno-Designed Molecules | Method for enhancing the presentation of exogenous antigen by human antigen-presenting cells and opsonized micro particle complexes for applying this method |
AU780182B2 (en) | 2000-03-22 | 2005-03-03 | Secretary Of State For Defence, The | Pharmaceutical composition for administration to mucosal surfaces |
AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
FR2859909B1 (fr) | 2003-09-22 | 2007-09-07 | Biomerieux Sa | Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation |
US20070275007A1 (en) | 2003-11-05 | 2007-11-29 | The Government Of The United States Of America, Represented By The Secretary Of Health And Human S | Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer |
WO2005072088A2 (en) | 2003-12-11 | 2005-08-11 | Sciperio, Inc. | Immunotherapy compositions, method of making and method of use thereof |
US9393215B2 (en) | 2005-12-02 | 2016-07-19 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
US8021689B2 (en) | 2006-02-21 | 2011-09-20 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | Nanoparticles for immunotherapy |
EP1991204A2 (en) | 2006-02-24 | 2008-11-19 | Novartis AG | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions |
JP2009541281A (ja) | 2006-06-20 | 2009-11-26 | シーエムピー セラピューティクス リミテッド | キチンマイクロ粒子を含む組成物およびそれらの医学的使用 |
US8333972B2 (en) | 2006-08-16 | 2012-12-18 | Temple University | Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions |
US20090202651A1 (en) | 2006-08-28 | 2009-08-13 | Moody Michael A | Antigen specific fluorescent nanoparticles |
AT504160A1 (de) | 2006-09-11 | 2008-03-15 | Ralf Dr Kircheis | Verwendung einer mehrkomponenten-tumorvakzine |
US20100151031A1 (en) | 2007-03-23 | 2010-06-17 | Desimone Joseph M | Discrete size and shape specific organic nanoparticles designed to elicit an immune response |
WO2009051837A2 (en) | 2007-10-12 | 2009-04-23 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9107858B2 (en) | 2007-12-05 | 2015-08-18 | Wisconsin Alumni Research Foundation | Dendritic cell targeting compositions and uses thereof |
CA2716622A1 (en) | 2008-02-26 | 2009-09-03 | The Regents Of The University Of California | Glycopeptides and methods of making and using them |
WO2010085509A1 (en) | 2009-01-20 | 2010-07-29 | Northwestern University | Compositions and methods for induction of antigen-specific tolerance |
-
2000
- 2000-09-14 AU AUPR0117A patent/AUPR011700A0/en not_active Abandoned
-
2001
- 2001-09-14 CA CA2422575A patent/CA2422575C/en not_active Expired - Fee Related
- 2001-09-14 ES ES01966829T patent/ES2363735T3/es not_active Expired - Lifetime
- 2001-09-14 IL IL15491301A patent/IL154913A0/xx unknown
- 2001-09-14 NZ NZ535851A patent/NZ535851A/en not_active IP Right Cessation
- 2001-09-14 PT PT01966829T patent/PT1326633E/pt unknown
- 2001-09-14 KR KR10-2003-7003743A patent/KR20030055262A/ko not_active Application Discontinuation
- 2001-09-14 EP EP01966829A patent/EP1326633B1/en not_active Expired - Lifetime
- 2001-09-14 WO PCT/AU2001/001160 patent/WO2002022164A1/en active IP Right Grant
- 2001-09-14 CN CNB018156452A patent/CN100446811C/zh not_active Expired - Fee Related
- 2001-09-14 DE DE60144240T patent/DE60144240D1/de not_active Expired - Lifetime
- 2001-09-14 US US10/380,588 patent/US20040014708A1/en not_active Abandoned
- 2001-09-14 NZ NZ524843A patent/NZ524843A/en not_active IP Right Cessation
- 2001-09-14 DK DK01966829.2T patent/DK1326633T3/da active
- 2001-09-14 AT AT01966829T patent/ATE501726T1/de active
- 2001-09-14 JP JP2002526413A patent/JP5198712B2/ja not_active Expired - Fee Related
-
2009
- 2009-10-21 US US12/603,439 patent/US8287877B2/en not_active Expired - Fee Related
-
2011
- 2011-10-27 US US13/283,294 patent/US8846026B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1630531A (zh) | 2005-06-22 |
KR20030055262A (ko) | 2003-07-02 |
JP2004507566A (ja) | 2004-03-11 |
PT1326633E (pt) | 2011-06-29 |
ES2363735T3 (es) | 2011-08-12 |
US8287877B2 (en) | 2012-10-16 |
IL154913A0 (en) | 2003-10-31 |
US8846026B2 (en) | 2014-09-30 |
NZ524843A (en) | 2004-11-26 |
US20100136043A1 (en) | 2010-06-03 |
AUPR011700A0 (en) | 2000-10-05 |
ATE501726T1 (de) | 2011-04-15 |
EP1326633A4 (en) | 2006-05-24 |
CA2422575A1 (en) | 2002-03-21 |
CN100446811C (zh) | 2008-12-31 |
JP5198712B2 (ja) | 2013-05-15 |
US20120082725A1 (en) | 2012-04-05 |
US20040014708A1 (en) | 2004-01-22 |
EP1326633B1 (en) | 2011-03-16 |
DE60144240D1 (de) | 2011-04-28 |
CA2422575C (en) | 2015-04-28 |
WO2002022164A1 (en) | 2002-03-21 |
NZ535851A (en) | 2006-04-28 |
EP1326633A1 (en) | 2003-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1326633T3 (da) | Sammensætning omfattende immunogene mikropartikler | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
DK1635863T3 (da) | Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål | |
WO2005037190A3 (en) | Multiplex vaccines | |
EP1594536A4 (en) | ADJUVANT INFLUENZA VACCINE | |
WO2004030608A3 (en) | Nanoemulsion vaccines | |
TR200102739T2 (tr) | Aşı | |
NZ596870A (en) | Vaccine compositions comprising a saponin adjuvant | |
NO20063254L (no) | Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist | |
IL150602A (en) | Proteosome influenza vaccine, method for preparing such and use thereof | |
DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
WO2006071989A3 (en) | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes | |
DE60136563D1 (de) | Salmonella vakzine | |
ATE551069T1 (de) | Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung | |
AU2001284354A1 (en) | Immunological adjuvant compounds, compositions, and methods of use thereof | |
WO2002034287A3 (en) | Therapeutic vaccine formulations containing chitosan | |
WO2003053338A3 (en) | Novel chimeric rev, tat, and nef antigens | |
WO2005012538A3 (en) | Accelerated vaccination | |
EA200301151A1 (ru) | Вакцина против натуральной оспы | |
ATE557034T1 (de) | Identifikation von epitopen und erniedrigung der allergenität von nahrungsmittelproteinen | |
WO2004058188A3 (en) | Vaccine compositions and methods | |
AU6761301A (en) | Adjuvant composition comprising fha protein or fragment of fha protein in free form | |
ATE505482T1 (de) | Impfstoff gegen infektiöses lachsanämievirus | |
AU2002342949A1 (en) | Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other | |
WO2002032455A3 (en) | Vaccine |